Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Cystex Urinary Pain Relief (methenamine / sodium salicylate)
- tobramycin
Interactions between your drugs
tobramycin sodium salicylate
Applies to: tobramycin, Cystex Urinary Pain Relief (methenamine / sodium salicylate)
MONITOR: The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods. Four children with cystic fibrosis who had been receiving chronic ibuprofen developed acute renal insufficiency shortly after initiation of IV aminoglycoside therapy for pulmonary exacerbations. An adolescent with CF who received intermittent, standard-dose ibuprofen during treatment with IV gentamicin also developed renal failure in addition to severe vestibular toxicity. Animal models suggest that renal prostaglandins may play a role in maintaining normal renal blood flow and glomerular filtration rate during the development of aminoglycoside nephrotoxicity, thus inhibition of their production by NSAIDs may worsen the renal damage.
MANAGEMENT: Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy. If concomitant administration is necessary, hydration status as well as renal and vestibular functions should be closely monitored.
MONITOR: In premature infants, NSAIDs may increase the plasma concentrations of aminoglycosides. The proposed mechanism is decreased aminoglycoside clearance due to NSAID reduction of glomerular filtration rate, which is already low in premature infants. In a study of 20 preterm infants who had been given at least three days of amikacin or gentamicin therapy, mean peak plasma concentration increased by 17% and 33%, and mean trough concentration increased by 29% and 48%, respectively, on day 1 following administration of IV indomethacin for patent ductus arteriosus. Serum creatinine increased by 17%, while urine output and serum sodium decreased. Six patients developed hyponatremia.
MANAGEMENT: It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants. During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.
References (6)
- Zarfin Y, Koren G, Maresky D, et al. (1985) "Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants." J Pediatr, 106, p. 511-3
- Scott CS, RetschBogart GZ, Henry MM (2001) "Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen." Pediat Pulm, 31, p. 314-6
- Kovesi TA, Swartz R, MacDonald N (1998) "Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis." N Engl J Med, 338, p. 65-6
- Gagliardi L (1985) "Possible indomethacin-aminoglycoside interaction in preterm infants." J Pediatr, 107, p. 991-2
- Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S (1996) "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci, 91, p. 187-91
- Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M (1985) "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol, 78, p. 386-94
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
VESIcare
Vesicare is used to treat symptoms of overactive bladder such as incontinence and frequent ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Detrol
Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and ...
Ditropan
Ditropan XL (oxybutynin extended release) is used to treat the symptoms of overactive bladder ...
Toviaz
Toviaz (fesoterodine) is used to treat overactive bladder with symptoms of urinary frequency ...
Urispas
Urispas is used for dysuria, urinary frequency, urinary incontinence
Ditropan XL
Ditropan XL is used for dysuria, neurogenic detrusor overactivity, urinary frequency, urinary ...
Botox Cosmetic
Botox Cosmetic is a prescription treatment for fine lines and wrinkles. It temporarily improves the ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.